BACKGROUND: Pancreatic cancer is among the most deadly cancers. Risk factors associated with the disease include age, race, sex, smoking status, and diabetes status. METHOD: We conducted a prospective analysis of risk factors and length of survival among pancreatic cancer patients living in Oklahoma between 1997 and 2012 (n=6,291). Kaplan-Meier survival curves were created followed by the log-rank test to compare difference in the survival time. Cox proportional hazard regression models were used to examine the strength of association through the estimated hazard ratios. RESULTS: The median survival time of the cohort was three months. Significant risk factors for reduced survival times included age, stage at diagnosis, and year of diagnosis. CONCLUSION: Results are in agreement with previous research findings. There have been small but noteworthy improvements in survival times for pancreatic cancer patients in Oklahoma. Length of survival during the study period was significantly associated with known risk factors such as age and stage of diagnosis.
BACKGROUND:Pancreatic cancer is among the most deadly cancers. Risk factors associated with the disease include age, race, sex, smoking status, and diabetes status. METHOD: We conducted a prospective analysis of risk factors and length of survival among pancreatic cancerpatients living in Oklahoma between 1997 and 2012 (n=6,291). Kaplan-Meier survival curves were created followed by the log-rank test to compare difference in the survival time. Cox proportional hazard regression models were used to examine the strength of association through the estimated hazard ratios. RESULTS: The median survival time of the cohort was three months. Significant risk factors for reduced survival times included age, stage at diagnosis, and year of diagnosis. CONCLUSION: Results are in agreement with previous research findings. There have been small but noteworthy improvements in survival times for pancreatic cancerpatients in Oklahoma. Length of survival during the study period was significantly associated with known risk factors such as age and stage of diagnosis.
Authors: Mark Chirumbole; Niraj Gusani; Alicia Howard; Tim Leonard; Peter Lewis; Josh Muscat Journal: Anticancer Res Date: 2009-08 Impact factor: 2.480
Authors: Patrick Maisonneuve; Albert B Lowenfels; H Bas Bueno-de-Mesquita; Parviz Ghadirian; Peter A Baghurst; Witold A Zatonski; Anthony B Miller; Eric J Duell; Paolo Boffetta; Peter Boyle Journal: Ann Epidemiol Date: 2010-02 Impact factor: 3.797
Authors: Jens Standop; Yvonne Kuhn; Tim R Glowka; Nico Schaefer; Marcus Overhaus; Volker Schmitz; Andreas Hirner; Jorg C Kalff Journal: Hepatogastroenterology Date: 2012 Nov-Dec
Authors: Pedro José Gutiérrez-Diez; Miguel Ángel López-Marcos; Julia Martínez-Rodríguez; Jose Russo Journal: Theor Biol Med Model Date: 2019-05-28 Impact factor: 2.432